行情

KMDA

KMDA

Kamada
NASDAQ

实时行情|Nasdaq Last Sale

6.89
+0.05
+0.68%
已收盘, 16:00 01/22 EST
开盘
6.93
昨收
6.85
最高
6.98
最低
6.75
成交量
12.94万
成交额
--
52周最高
8.00
52周最低
4.908
市值
2.78亿
市盈率(TTM)
8.09
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

KMDA 新闻

  • Kamada Announces $25M Private Placement With FIMI Opportunity Fund; Co. To Issue ~4.17M Shares To FIMI At $6/Share
  • Benzinga.1天前
  • Kamada Announces $25 Million Private Placement with FIMI Opportunity Fund
  • GlobeNewswire.1天前
  • Why Kamada (KMDA) Could Beat Earnings Estimates Again
  • Zacks.5天前
  • Kamada Sees Prelim. Q4 Sales $31.4M-$32.4M vs $35.4M Est., FY19 Sales $126.5M-$127.5M vs $130.47M Est.; Sees FY20 Sales $132M-$137M vs $121.51M Est.
  • Benzinga.01/07 12:05

更多

所属板块

制药
-0.33%
制药与医学研究
-0.23%

热门股票

名称
价格
涨跌幅

KMDA 简况

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises Protosol to reduce blood loss in patients undergoing cardiac surgery; Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other.
展开

Webull提供Kamada Ltd.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。